Get started

SYNGENE

SYNGENE: A Confluence of Demand Zones Worth Watching Understanding the market moves through the lens of demand and supply zones can give traders a critical edge. I’ve been looking at SynGene International ( NSE:SYNGENE ), and I think it’s at a super interesting level right now. Let me break it down for you in a simple way! 📈 Why SynGene Looks Promising Right Now Triple Timeframe Demand Zone Confluence : NSE:SYNGENE is trading in demand zones across the 75-minute, 125-minute, and daily timeframes. This rare alignment of zones suggests that "smart money" may be active here. Demand zones represent areas where unfilled buy orders are likely to exist, making this confluence a highly positive factor for demand-supply zone traders. Absence of Supply Zones : No supply zones are visible on the current timeframes or even on the weekly chart. This indicates that price movement may face minimal resistance ahead. The absence of supply zones on the higher timeframe (weekly) places the stock in a "wholesale area" as per Curve (location) analysis. Quality Demand Zone : The demand zones currently in play were instrumental in driving the price to an all-time high in the past. These zones follow-through candles broken multiple tested resistance levels, demonstrating their strength. Act of Polarity : While the price is not precisely in the demand zone right now, it is trading at a level that previously acted as resistance. This "act of polarity" (where resistance becomes support) adds another layer of technical validity to this setup. Uptrend on Higher Timeframe : The higher timeframe trend for SynGene remains upward, aligning well with the idea of buying on demand zones. 🎯 Key Trading Considerations - Entry Strategy : Look for entry opportunities near the demand zone, ensuring your stop-loss (SL) is placed below the distal line of the demand zone with a buffer. - Risk Management : Aim for a minimum 1:2 risk-reward ratio for your first target. If the price moves further upward, consider trailing your stop-loss to capture extended rallies. - Safety is Key : While the setup is promising, remember that no setup is foolproof. Discipline with stop-losses. Lastly, thank you for your support. Feel free to ask if you have any questions. 📢 Disclaimer : This analysis is purely for educational purposes and is not intended as a trading or investment recommendation. Please note, I am not a SEBI-registered analyst. Always consult with a financial professional before making trading or investment decisions.
NSE:SYNGENELong
by AfnanTAjuddin
SYNGENE - Ichimoku Breakout📈 Stock Name - Syngene International Limited 🌐 Ichimoku Cloud Setup: 1️⃣ Today's close is above the Conversion Line. 2️⃣ Future Kumo is Turning Bullish. 3️⃣ Chikou span is slanting upwards. All these parameters are shouting BULLISH at the Current Market Price and even more bullishness anticipated AFTER crossing 926. 🚨Disclaimer: This is not a Buy or Sell recommendation. It's for educational purposes and a guiding light to learn trading in the market. #CloudTrading #IchimokuCloud #IchimokuFollowers #Ichimokuexpert Excited about this analysis? Share your thoughts in the comments below! 👍 Like, Share, and Subscribe for daily market insights! 🚀 #StockAnalysis #MarketWatch #TradingEducation #ichimoku #midcap #smallcap #largecap #SYNGENE
NSE:SYNGENELong
by nikunjbhadja
SYNGENE - Demand zone tapped: Ready for a move of 50%! Trade Idea Description: Despite weak earnings, the potential for better quarterly results could trigger a breakout. Here’s the plan: - Entry Point: At CMP 691 - Stop Loss: 10% below the entry around 640 on candle closing basis. - Target: Aiming for a 50% upside, 1:5 risk-reward ratio With minimal downside risk, this is a compelling long-trade opportunity. - Stay updated for further insights and trade safely! - If you have liked the analysis, don't forget to leave a comment and boost the post. Happy trading! Disclaimer: This is NOT a buy/sell recommendation. This post is meant for learning purposes only. Please, do your due diligence before investing. --- Thanks & Regards, Anubrata Ray
NSE:SYNGENELong
by SuperNova396
Trade Smart in Turbulent Times in SyngeneNSE:SYNGENE , a leading global discovery, development and manufacturing organization catering to the pharmaceutical and biotech industries, is under the spotlight for this week's technical analysis. Entry Logic 🎯: The stock has recently crossed its 50-day moving average (MA) of INR 799, additionally breaching the Fibonacci retracement level of 0.382 at INR 810 . These factors, combined with potential bullish crossovers in Exponential Moving Average Divergence (EMD) and Moving Average Convergence Divergence ( MACD) (12,26,9), lay down a fertile ground for upward movement. The ideal entry point would be upon a strong opening above I NR 810.2 or INR 811.60 (0.5 Fibonacci level). Target Levels 🎯: Target 1: INR 823.45 Target 2: INR 843.70 These targets are set based on historical resistance zones and projected upward momentum. Exit Logic 🚪: An exit should be considered if momentum drops or reverses before reaching the target levels, or upon hitting the targeted price points for desired profits. Stop Loss ⚠️: A stringent stop loss is advised at INR 786. This is a slightly aggressive level aimed at limiting losses should the market sentiment change abruptly. Technical Indicators 📊: MACD: Awaiting a bullish crossover to substantiate entry. Stochastics: Recent crossover observed, bullish sign. RSI: Also in bullish crossover territory. %R: Currently in oversell territory - positive. Fisher 9: Indicating strong buy signal. Market Sentiment 🌐: With the broader Indian market expected to exhibit volatility in the forthcoming week, caution is advisable. The high PE ratio of 64.44 and a modest EPS of 12.06 underscore a relatively high valuation, with a low payout ratio of 4.16. Recommendation 📝: Syngene International presents a potentially lucrative short-term swing trading opportunity for aggressive traders. The anticipated bullish momentum, if actualized, could render fruitful returns; albeit the inherent market risks necessitate a robust exit strategy and a firm stop loss. Disclosures and Disclaimers 📢: This analysis is for informational purposes only and not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. The report is based on historical data and prevailing market conditions; the future may unfold differently. All investors are advised to conduct their independent research or consult a financial advisor before making any investment decisions.
NSE:SYNGENELong
by finogent
Syngene India- Basing out & risks to consider before getting inSyngene has been a star performer in the F&O space. I personally had this position on and sold off near 750. Now it gave shakeout down to 735 and seems to be setting up again. Risks to consider if looking at the stock Earnings coming up - should be good, but a risk always Overall pharma sector looking good & breaking upwards which is positive This stock tends to give shakeouts of about 2-3% down (did it once from 730 back to 690 and then from 770 back to 730. So if you get in, size accordingly and dont keep tight stop Selling put spreads when it does give a shakeout is probably the very best way to play this stock (until it breaks the 21 EMA - which at some point it will) Keep an eye on volumes - every previously shakeout was on lower than average vols Use the F&O as well as cash equity to get the best out of this name - happy trading.
NSE:SYNGENELong
by kunal_finner
2
SYNGENE - Ichimoku BreakoutStock Name - Syngene International Limited Ichimoku Cloud Setup : 1). Today's close is above the Conversion Line 2). Future Kumo is Turning Bullish 3). Chikou span is slanting upwards All these parameters are showing bullishness at Current Market Price and more bullishness AFTER crossing 782 #This is not Buy and Sell recommendation to any one. This is for education purpose and a helping hand to learn trading in Market. # Cloud Trading # Ichimoku Cloud # Ichimoku Followers I hope you all like my analysis. Please do share your thoughts into comment section. Please give a like, share & subscribe for daily analysis.
NSE:SYNGENELong
by nikunjbhadja
SYNGENESYNGENE:- Stock has given breakout, after almost 2 years, if you want to plan something, then go back to 685-695, then plan something, till then keep an eye Hello traders, As always, simple and neat charts so everyone can understand and not make it too complicated. rest details mentioned in the chart. will be posting more such ideas like this. Until that, like share and follow :) check my other ideas to get to know about all the successful trades based on price action. Thanks, Ajay. keep learning and keep earning.
NSE:SYNGENELong
by AjayDhakad_Keep_it_simple
SYNGENE INTERNATIONAL : STRENGTH OF 2.5 YRS OF CONSOLIDATIONSyngene International Limited is an India-based contract research company. The Company is engaged in providing services from early discovery and development to commercial manufacturing for small and large molecules and a Market Cap of Rs. 24,500+ Cr. The chart is moving within a limited range since 2020 , for almost 2.5 years. Though the range is high but is limited , from 510 to 680. The stock remained untouched from the relative movements in Pharma Sector as well as market as whole. The stock is now consolidating. When a stock is ready to come out any range, the bottoms get higher and higher as we seen in the chart , the bottoms are getting higher since Jun 2022. We are seeing Symmetrical Triangle Pattern. We see breakout of this pattern last week and since then the stock is consolidating. The next resistance is from 650 to 690, which is stock's life time high. If the stock crosses this level, there is possibility of a new trend , strong trend , with a gained momentum of last 2.5 years. Symmetrical Triangle is completed and is already broken out , pattern is strong , high consolidation of 2.5 Years and 50 EMA Support , all these factors , indicates a break out in of this chart. Entry @ CMP : 609 Targets : 650 , 690 , and if breaks the range (high possibility ) thereafter a new positive trend ... Stop Loss : 605 This analysis is only for education purpose. Please do your own analysis before entering into any trade and trade at your own risk. Best Of Luck !!!
NSE:SYNGENELong
by chakraveer1104
► ADVANCE PATTERN #29: SYNGENE ◄► ADVANCE PATTERN #29: SYNGENE ◄ 📌 Levels are mentioned on chart for ❝Swing trading❞. ☆ Please check the description section ⌨ for early entry level in given stock ₪ to get better Risk to Reward (☈☈) ratio. ☆ Kindly like & share ➥ this pattern. Comment ⎚ with what do you think. Follow me @ tradingview for more updates and like the chart ❤!!! Entry: ▲ 630 SL: ☢ 605 Target: ➚ 705 RR: ☈ 1:3.0 ☆ Thank you. Happy Trading!!! Best Regards, 𝘿𝙧. 𝙎𝙝𝙖𝙢𝙧𝙖𝙟𝙖 𝙉𝙖𝙙𝙖𝙧 𝙋𝙝𝘿 𝙞𝙣 𝙏𝙚𝙘𝙝𝙣𝙤𝙡𝙤𝙜𝙮. ✮ Disclaimer ✮ -------------------------------------------------------- All investments involve risk, and the past performance of a security, industry, sector, market, financial product, trading strategy, or individual’s trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. Such decisions should be based solely on an evaluation of their financial circumstances, investment objectives, risk tolerance, and liquidity needs. ---------------------------------------------------------  
NSE:SYNGENELong
by Profitable_Traders
Syngene international fundamental and technical analysis About company Syngene initiated their operations as a CRO in 1994 with services in chemistry and biology. Syngene International offers integrated solutions across research, development and manufacturing facilities. Sector Overview The Indian pharmaceutical industry is currently valued at $50Bn. India is a large exporter of pharmaceuticals with over 200 countries that receive Indian Pharma exports. The industry growth has been at a CAGR of 9.43% over the last 9 years. Sector Outlook The pharma industry in India is expected to reach $65Bn by 2024 & $130Bn by 2030. India is the world’s largest supplier of generic medications; which account for 20% of the worldwide supply by volume & supply about 60% of the global vaccination demand. Company’s business Syngene International has over 400 active clients and have 15 collaborations with the top 20 pharmaceutical companies. Their sector expertise includes pharmaceuticals, biotech, nutrition, animal health, consumer goods and speciality chemicals. About the segments Syngene International has their presence in the following segments: •Discovery Services •R&D Centres •Development Services •Manufacturing Services Q3 Numbers Revenue up from ₹768 Cr in Q2 to ₹787 Cr in Q3 OPM up from 28% to 29% NPAT up from 102Cr to 110Cr EPS up from ₹5.53 to ₹2.73 Key Highlights: Performance is excluding impact of Remdesivir manufacturing which had high sales growth the during first quarter of the last financial year. No sales have been recorded in 9MFY23. Revenue from operations grew by 23% YoY, excluding Remdesivir; 28% YoY Revenue growth driven by Discovery Service division & manufacturing division; Biologics. Capex for 9M at HKEX:50 mn Started a program of HKEX:30 mn for a new facility & the Capex will be reflected on the books in the next few Qtrs depending on execution EBITDA up 15% YoY Effective tax rate up from 19% to 21.5% YoY; however, they have a MAT credit of ₹160Cr that will be utilised over the next few years & will keep cash outflow for income tax at minimum pertained tax level Depreciation and amortisation up by 21% YoY due to new investments Recently completed facility will offer end-to-end solutions in drug production development & manufacturing for clinical supplies for small & large molecules Expect the completion of additional 24,000 sqft of lab space, a new compound & mgmt facility in the current qtr. Key Strengths Increase in number of collaborations with emerging biopharma companies Expect to start GMP production this quarter with the completion of sterile fill-finish facility for small scale clinical manufacturing FIIs and DIIs have increased holdings QoQ PAT growth at 5% YoY Completed the US FDA, EMEA and MHRA regulatory audits for commercial scale biologics manufacturing facility Received cGMP certifications from regulatory agencies which put them on track to manufacture drug substance on a commercial scale Weakness PAT growth for full year expected to be in single digits Operating EBITDA margin down from 31.7% in Q3 FY22 to 29.4% in Q3 FY23 EBITDA margin for 9M at 29.7% compared to 31% last year Hedge losses in Q3 FY23 at ₹16Cr compared to a hedge gain of ₹20Cr EBITDA growth lower than revenue growth due to low scale and capacity utilisation in manufacturing Material costs up by 6% YoY Lowest dividend yield in pharma sector Finance cost up from ₹9.4Cr to ₹13.7Cr due to rising interest rates; • Numbers and Ratios Market Cap: ₹24,076 Cr. Stock P/E: 55.9 RoCE: 13.3% RoE: 13.6% PEG: 7.25 Price to Sales: 8.14 Int Coverage: 14.3 NPM: 13.9% D/E: 0.31 • Shareholding Pattern Promoter: 64.86% FII: 16.87% DII: 7.03% Public: 10.77% Others: 0.47% Conclusion The company has expanded its facilities and capabilities, receiving regulatory certifications for commercial-scale biologics manufacturing. While operating EBITDA margin has declined, completion of a sterile fill-finish facility & GMP production is expected to boost profitability.
BSE:SYNGENE
by biokon70